1. Home
  2. MLYS vs SPTN Comparison

MLYS vs SPTN Comparison

Compare MLYS & SPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • SPTN
  • Stock Information
  • Founded
  • MLYS 2019
  • SPTN 1917
  • Country
  • MLYS United States
  • SPTN United States
  • Employees
  • MLYS N/A
  • SPTN 17000
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • SPTN Food Distributors
  • Sector
  • MLYS Health Care
  • SPTN Consumer Discretionary
  • Exchange
  • MLYS Nasdaq
  • SPTN Nasdaq
  • Market Cap
  • MLYS 526.1M
  • SPTN 630.9M
  • IPO Year
  • MLYS 2023
  • SPTN N/A
  • Fundamental
  • Price
  • MLYS $10.21
  • SPTN $18.69
  • Analyst Decision
  • MLYS Strong Buy
  • SPTN Hold
  • Analyst Count
  • MLYS 2
  • SPTN 1
  • Target Price
  • MLYS $30.00
  • SPTN $20.00
  • AVG Volume (30 Days)
  • MLYS 263.5K
  • SPTN 248.1K
  • Earning Date
  • MLYS 03-20-2025
  • SPTN 02-12-2025
  • Dividend Yield
  • MLYS N/A
  • SPTN 4.71%
  • EPS Growth
  • MLYS N/A
  • SPTN 9.92
  • EPS
  • MLYS N/A
  • SPTN 1.33
  • Revenue
  • MLYS N/A
  • SPTN $9,532,883,000.00
  • Revenue This Year
  • MLYS N/A
  • SPTN N/A
  • Revenue Next Year
  • MLYS N/A
  • SPTN $2.15
  • P/E Ratio
  • MLYS N/A
  • SPTN $14.06
  • Revenue Growth
  • MLYS N/A
  • SPTN N/A
  • 52 Week Low
  • MLYS $8.58
  • SPTN $17.30
  • 52 Week High
  • MLYS $16.91
  • SPTN $23.00
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 44.53
  • SPTN 56.59
  • Support Level
  • MLYS $9.57
  • SPTN $17.77
  • Resistance Level
  • MLYS $10.79
  • SPTN $18.66
  • Average True Range (ATR)
  • MLYS 0.64
  • SPTN 0.40
  • MACD
  • MLYS 0.11
  • SPTN 0.11
  • Stochastic Oscillator
  • MLYS 63.98
  • SPTN 96.19

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About SPTN SpartanNash Company

SpartanNash Co is a food solutions company that delivers the ingredients. Its principal business activities include, distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores, and U.S. military commissaries and exchanges; as well as operating a fresh produce distribution network and the Our Family private label brand. The company operates in two segments: Retail and Wholesale. Majority of the revenue is earned from its Wholesale segment which uses a multi-channel sales approach to distribute national brand and private brand products to independent retailers, national accounts, food service distributors, e-commerce providers, and the Company's corporate owned retail stores.

Share on Social Networks: